The United Kingdom and the United States have reached a major bilateral deal that will guarantee zero import taxes on British medicine products being sold in the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has agreed to raise spending on medicines through the NHS. This commitment guarantees that tariffs on these vital products will stay at zero for a duration of the next three years.
This development follows earlier warnings to dramatically increase import taxes on patented drug products, with increases floated as high as double the cost.
"This agreement with the UK bolsters the worldwide climate for new treatments and establishes long-overdue balance to U.S.–U.K. drug exports," an announcement said.
Trade Significance
Medicines represent one of the UK's biggest exports to the America, which is clearly the primary market for major UK drugmakers.
Trade data show that in the one-year period prior to the third quarter, the UK sold medicines valued at £11.1bn to the US. This amount accounted for nearly one-fifth of British export trade in that span.
"This agreement protects work, increases capital expenditure and sets the stage for the UK to become a global hub for life sciences," a minister stated.
Key British Pledges
The agreement involves several key commitments from the United Kingdom:
- Revised Affordability Limit: The UK will lift the price threshold at which it deems new therapies to be unaffordable by 25%.
- Higher Drug Budget: There is a goal to raise overall public funding on treatments from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage manufacturers must refund to the NHS to prevent overspending will be restricted at fifteen percent. In the past, refunds exceeded twenty percent.
Industry Background
The pact follows a ongoing tension between the pharmaceutical industry and the UK government over drug pricing and approval rates.
This friction were heightened by claims that US patients were paying significantly more for the equivalent treatments than patients in the UK and Europe.
Over the last 18 months, several significant manufacturing plans in the UK have been paused or cancelled, while major funding commitments have been announced toward American operations.
The Science Minister acknowledged that the NHS had to spend more on medicines, noting that its spending on drugs had shrunk as a share of its total funding over the previous ten-year period.
